Skip to main content
134 search results for:

Response criteria 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 10-04-2018 | Response criteria | Article

    iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

    Seymour L et al. Lancet Oncol 2017; 18(3): e143–e152. doi:10.1016/S1470-2045(17)30074-8

  2. 07-03-2017 | CNS metastases | Article

    Comparing available criteria for measuring brain metastasis response to immunotherapy

    Here we report a comparison between available response criteria when used to evaluate CNS response of patients from a Phase II trial studying the effect of pembrolizumab in patients with previously untreated or progressive melanoma or lung cancer brain metastases. Qian JM et al. J Neurooncol 2017. doi:10.1007/s11060-017-2398-8

  3. 04-07-2023 | Non-small-cell lung cancer | News | Article

    Adagrasib shows intracranial efficacy in KRYSTAL-1 trial

    Over a median follow-up of 13.7 months, treatment with adagrasib resulted in an intracranial objective response rate, as per the CNS RECIST v1.1 criteria, of 42% among the 19 evaluable patients.

  4. 20-04-2023 | Urothelial cancer | At a glance | Article

    At a glance: Second and later line immunotherapy for advanced urothelial carcinoma

    OS was a median 8.7 months in the full cohort, rising to a median 10.0 months among the subgroup of patients who met the IMvigor211 entrance criteria.

  5. 06-04-2023 | Breast cancer | News | Article

    Anthracycline-related heart failure risk highlighted for breast cancer, lymphoma survivors

    Hector Villarraga (Mayo Clinic, Rochester, Minnesota, USA) and co-authors were unable to confirm a dose–response relationship between anthracycline use and CHF, finding no significant difference in the risks associated with cumulative doxorubicin or equivalent doses of less than 180 mg/m 2 , 180–250 mg/m 2 , or more than 250 mg/m 2 .

  6. 16-01-2023 | Urothelial cancer | News | Article

    Neoadjuvant gemcitabine–cisplatin ‘a viable option’ for high-grade UTUC

    The primary endpoint of the study was pathological response after neoadjuvant treatment (defined as < ypT2N0) – this was achieved by 63% of patients and “met the prespecified criteria to be considered promising”, say the investigators.

  7. 28-10-2022 | Non-small-cell lung cancer | News | Article

    Real-world study adds support for osimertinib for uncommon EGFR mutations

    Osimertinib elicits high rates of systemic and intracranial response in people with advanced non-small-cell lung cancer harboring uncommon EGFR mutations, say the authors of the real-world UNICORN study.

  8. 05-09-2022 | Lung cancer | News | Article

    First-line cemiplimab prolongs advanced NSCLC survival irrespective of PD-L1 expression

    Median progression-free survival (PFS) was also significantly longer with cemiplimab versus placebo (8.2 vs 5.0 months), while the objective response rate (ORR) was significantly higher (43.3 vs 22.7%) and the median response duration significantly longer (15.6 vs 7.3 months).

  9. 23-09-2022 | ESMO 2022 | Conference coverage | Article

    Advanced RCC PFS boost with addition of cabozantinib to first-line dual immunotherapy

    Just 8% of participants in the cabozantinib arm had progressive disease as the best response compared with 20% of those in the placebo arm.

  10. 06-08-2021 | Urothelial cancer | Feature | Article
    Updated January 2023

    At a glance: First-line immunotherapy for advanced urothelial carcinoma

    After a median follow-up of 56.3 months, the ORR was 29.0%, the median duration of response was 33.4 months, and 39.4% of responders had an ongoing response at 48 months.

  11. 11-08-2022 | WCLC 2022 | Conference coverage | Article

    Sugemalimab continues to show stage III unresectable NSCLC benefits after chemoradiation

    The investigator also observed that a similar proportion of the sugemalimab and placebo arms achieved a response to treatment (24.5 vs 25.2%), but patients given sugemalimab had a significantly longer median duration of response, at 24.1 months versus 6.9 months with placebo.

  12. 07-06-2022 | ASCO 2022 | Conference coverage | Article

    OS data reported from TheraP trial of LuPSMA in mCRPC

    Hofman also presented the OS data for the 61 so-called “screen-fail” patients who met all the inclusion and exclusion criteria but were excluded from the trial as a result of low PSMA levels or FDG discordance.

  13. 04-06-2022 | ASCO 2022 | Conference coverage | Article

    No benefit of maintenance cabozantinib in unselected patients with mUC

    The hazard ratio for progression or death of 0.89 numerically favored the multikinase inhibitor but did not meet the prespecified criteria for statistical significance.

  14. 16-05-2022 | Breast cancer | News | Article

    WSG-ADAPT data may help guide chemotherapy use for HR-positive, HER2-negative EBC

    The use of adjuvant chemotherapy in patients with hormone receptor-positive, HER2-negative early breast cancer and up to three positive lymph nodes could be guided by the 21-gene recurrence score and response to preoperative endocrine therapy, research suggests.

  15. 11-04-2022 | ALK-mutated NSCLC | Interview | Article

    Pathologic testing for ALK and ROS1 aberrations in NSCLC

    And for ROS1, copy number variation in ROS1 doesn't seem to have any impact on resistance or response to treatment.

  16. 22-02-2022 | ASCO GU 2022 | Conference coverage | Article

    ​​​​​​​NeoAvAx shows promise of neoadjuvant avelumab–axitinib for localized high-risk RCC

    The NeoAvAx trial has demonstrated encouraging response and disease-free survival after neoadjuvant treatment with avelumab plus axitinib in people with locally advanced renal cell carcinoma at high risk for relapse after nephrectomy.

  17. 20-02-2022 | ASCO GU 2022 | Conference coverage | Article

    Maintenance rucaparib feasible for platinum-responsive mUC with DRD biomarkers

    He explained that the trial was designed to recruit 48 patients with mUC who had achieved a complete or partial response or stable disease after 4–8 cycles of platinum-based chemotherapy and who had met the study’s criteria for DRD, defined as at least 10% genome-wide loss of heterozygosity, a somatic alteration in one of 15 DRD genes, or a germline BRCA1 or BRCA2 mutation.

  18. 20-02-2022 | ASCO GU 2022 | Conference coverage | Article

    ​​​​​​​Combined nivolumab, axitinib treatment elicits good response in metastatic RCC

    Combination treatment with nivolumab plus axitinib has achieved a high response rate in patients with metastatic renal cell carcinoma enrolled in a phase 1/2 trial.

  19. 07-02-2022 | Non-small-cell lung cancer | News | Article
    News in brief

    Continuing lorlatinib beyond progression beneficial for some ALK-positive NSCLC patients

    The researchers identified 102 patients who achieved a complete response, partial response, or stable disease for at least 6 weeks in response to treatment with lorlatinib 100 mg/day before experiencing disease progression as defined by RECIST criteria.

  20. 06-12-2021 | Non-small-cell lung cancer | Interview | Article

    ARROW points the way for RET fusion-positive NSCLC treatment

    The eligibility criteria were pretty standard for ARROW.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.